ArticleNPJ breast cancer2026
Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival.Breast cancer research and treatment · 2026Article
- The Assessment of Race, the 21-Gene Recurrence Score, and Breast Cancer Outcomes at Kaiser Permanente.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
We compared clinicopathologic features, MammaPrint and BluePrint molecular subtype, and outcomes by race among females with hormone receptor-positive (HR+), HER2- early-stage breast cancer (EBC). Of 1018 participants with HR+ HER2- EBC enrolled from two registries (BEST and FLEX), 509 White females were propensity score matched 1:1 to 509 Black females based on age and/or menopausal status. MammaPrint classified tumors as High-Risk or Low-Risk; and together with BluePrint, classified tumors as Luminal A-Type, Luminal B-Type, or Basal-Type. Recurrence-free survival (RFS) was analyzed by race and molecular subtype. Cox proportional hazards models assessed association of clinicopathologic features with outcomes. Basal-Type tumors were more prevalent among Black vs White participants (11.0% vs 4.8%, p < 0.001). Independent of race, participants with Basal-Type tumors had lower 3-year RFS (83.7%) compared to Luminal B-Type (93.7%) and Luminal A-Type (96.5%, p < 0.0001). Multivariate analysis revealed that participants with High-Risk, Luminal B- and Basal-Type tumors had significantly worse 3-year outcomes compared to Low-Risk Luminal A-Type, after controlling for race and potential confounders. Genomic classification identified higher proportions of High-Risk HR+ HER2- EBC among Black participants. Molecular subtype was independently prognostic of 3-year survival, supporting the prognostic and potentially predictive importance of genomic testing to reduce racial survival disparities among Black females with EBC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.